Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling

• DOI: 10.1016/j.crmeth.2023.100654
• Publication Date: 2023-12-07T15:36:44Z
• Authors: Aram N. Andersen; Andrea M. Brodersen; Pilar Ayuda-Durán; Laure Piechaczyk; Dagim Shiferaw Ta...; Lizet Baken; Julia Fredriksen; Mia Stoksflod; Andrea Lenartova; Yngvar Fløisand; Sigrid S. Skånland; Jorrit M. Enserink
• Keywords: Ex vivo

Current treatment selection for acute myeloid leukemia (AML) patients depends on risk stratification based cytogenetic and genomic markers. However, the forecasting accuracy of response remains modest, with most receiving intensive chemotherapy. Recently, ex vivo drug screening has gained traction in personalized as a tool mapping patient groups relevant cancer dependencies. Here, we systematically evaluated use sensitivity profiling predicting survival clinical to chemotherapy cohort AML patients. We compared computational methodologies scoring efficacy characterized tools counter noise batch-related confounders pervasive high-throughput testing. show that is robust versatile approach prognostics comprehensively maps functional signatures disease progression. In conclusion, can assess individual may guide decision-making.